First attempts were performed for advanced renal cell carcinoma and metastatic melanoma: recombinant human interleukin-2 (rhIL-2) used in these settings, was capable of favoring human T cell growth [1,2]. This evidence concerns the gene IL2 and renal cell carcinoma.